Can I Take Quercetin with Testosterone Cypionate?

What the Testosterone Cypionate Label Says About Interactions

The Depo-Testosterone label (testosterone cypionate, intramuscular) has a short drug interaction section, and quercetin is not in it [1]. It names three things:

• Oral anticoagulants. Androgens may increase sensitivity to oral anticoagulants, and the anticoagulant dose may need to be reduced [1].
• Oxyphenbutazone. Concurrent use may raise serum oxyphenbutazone levels [1].
• Insulin and diabetes medicines. Androgens may lower blood glucose and insulin requirements [1].

Where the CYP3A4 Warning Comes From

Quercetin is a plant flavonol sold as a dietary supplement. A Drugs@FDA search returns no approved drug application with quercetin as the active ingredient, so it is not an FDA-approved treatment for anything [3]. Laboratory and rodent work has often described quercetin as a CYP3A inhibitor [2].

Human data go the other way. In a randomized two-period crossover study, 18 healthy men took 500 mg of quercetin daily for 13 days, then a single 7.5 mg dose of midazolam, a standard CYP3A probe. In carriers of CYP3A5*1 alleles, midazolam AUC0-inf fell from 211.8 to 165.5 ng h/mL (p<0.01) and half-life fell from 2.75 to 2.06 hours. The authors read this as induction of CYP3A activity [2].

In human liver samples, 6-beta-hydroxylation was the main oxidative pathway measured for testosterone and was linked to a CYP3A-family enzyme [4]. That does not establish what quercetin does to testosterone levels after a cypionate injection; that has not been measured.

What Quercetin Has Done to Other Drugs in People

Human studies of quercetin give a mixed picture, with the direction depending on the enzyme and the drug tested [2][5][6][7][8][9][10].

• Diclofenac (CYP2C9). Twelve healthy volunteers took 500 mg of quercetin twice daily for 10 days. Diclofenac peak concentration, AUC and half-life rose, oral clearance fell, and formation of the 4-hydroxy metabolite fell, consistent with CYP2C9 inhibition [5].
• Chlorzoxazone (CYP2E1). Twelve healthy subjects on the same 10-day regimen. Chlorzoxazone Cmax rose 47.8%, AUC 69.3% and half-life 36.4%; clearance fell 41.6% [9].
• Caffeine (CYP1A2). Twelve volunteers took 500 mg daily for 13 days. A urinary marker of CYP1A2 activity fell 10.4% (95% CI 1.1 to 29.8%), a small change, while CYP2A6 activity rose 25.3% [11].
• Fexofenadine (P-glycoprotein). Twelve subjects took 500 mg three times daily for 7 days. Fexofenadine AUC rose 55% (2,005 to 3,099 ng h/mL) and Cmax rose 68% [6].
• Talinolol (P-glycoprotein). Eighteen subjects took 500 mg daily for 13 days. Talinolol AUC fell (8,415 vs 10,478 ng h/mL, p=0.03), the opposite of the fexofenadine result [10].
• Saquinavir. Ten adults took 500 mg three times daily for 8 days. Plasma saquinavir was unchanged (AUC ratio 0.99, 95% CI 0.65 to 1.50) [7].
• Cefprozil. Twenty-four men took 500 mg daily for 15 days. Cefprozil exposure did not change (Cmax 8.18 vs 8.35 microgram/mL) and no serious adverse events were reported [8].

So quercetin raised exposure to three drugs (diclofenac, chlorzoxazone, fexofenadine), lowered it for two (midazolam, talinolol) and left two unchanged (saquinavir, cefprozil). There is no single quercetin effect to apply to a new drug. The diclofenac and chlorzoxazone studies were small and open-label, and their results are consistent with CYP2C9 and CYP2E1 inhibition [5][9].

What to Watch on Testosterone Cypionate Itself

The Depo-Testosterone intramuscular label has no boxed warning [1]. Three things the label or FDA flags:

Hematocrit. The label calls for periodic hemoglobin and hematocrit checks during long-term use and lists polycythemia among adverse reactions [1]. A network meta-analysis of 29 placebo-controlled trials (3,393 men) covering several testosterone formulations found that intramuscular enanthate or cypionate raised mean hematocrit by 4.0% (95% CI 2.9 to 5.1) versus placebo, compared with 1.4% for patches [12]. A retrospective review of 178 hypogonadal men found erythrocytosis (hematocrit above 50%) in 66.7% of those on injectable testosterone versus 12.8% on gels; the injection group was younger and started with a higher hematocrit, and the study was not randomized [13].

Blood pressure. FDA's February 2025 labeling action states that ambulatory blood pressure studies confirmed a blood pressure increase with all testosterone products, class-wide [14]. The cypionate label says testosterone can increase blood pressure, that it should be measured periodically, especially in men with hypertension, and that testosterone products are not recommended in uncontrolled hypertension [1].

Gynecomastia. The label lists gynecomastia among adverse reactions and says it may occasionally persist [1]. Most gynecomastia results from deficient androgen action or excessive estrogen action in breast tissue [15].

Quercetin Dose, Form and Safety Record

Human studies used 500 mg once daily for 13 days [2], 15 days [8], or 4 weeks [16]; 500 mg twice daily for 10 days [5]; and 500 mg three times daily for 7 or 8 days [6][7]. These were study doses, not recommendations.

Formulation changes exposure a lot. In a meta-analysis of 31 human intervention studies, a lecithin phytosome delivered about 20.1 times the bioavailability of quercetin aglycone [17]. A single dose of onion-skin extract gave 4.8 times the AUC and 5.4 times the Cmax of quercetin dihydrate capsules [18]. In ileostomy volunteers, absorption was 24% for pure aglycone, 52% for onion glucosides and 17% for rutinoside; in people with an intact colon, plasma quercetin declined with a half-life of about 25 hours [19].

On safety, a review of supplemental quercetin found adverse effects rarely reported and mild, but concluded there are no adequate data on long-term use beyond 12 weeks at 1,000 mg/day or more [20]. The interaction study with the clearest safety reporting, 24 men taking 500 mg daily for 15 days, reported no serious adverse events [8]. Quercetin's best-supported effect in randomized trials is small: a meta-analysis of 7 trials (587 patients) found systolic blood pressure 3.04 mmHg lower and diastolic 2.63 mmHg lower, with the effect present at 500 mg/day or more but not below that dose [21].

The Practical Answer for a Man on Cypionate

Small human studies found CYP2C9 and CYP2E1 inhibition, while the one human CYP3A probe study showed induction rather than inhibition [2][5][9]. What the label and FDA flag on cypionate is hematocrit and blood pressure [1][14].